Archive · 8 Oct 2026
Nomura Cuts PB Fintech Target After Proposed Insurance Commission Caps
PB Fintech is a company that sells insurance products.
Its shares have fallen nearly 45% in recent weeks as investors consider a proposal to limit insurance commissions.
Nomura lowered the price it thinks the shares could reach, but kept its rating at Neutral.
In its main forecast, the brokerage expects much lower profits in FY28 and FY29 than it had previously estimated.
It also considered what might happen if health insurance commission limits were a little higher.
Under that assumption, its FY28 profit estimate would be higher than in the main forecast.
Another scenario assumes the company sells traditional savings products.
Nomura says that could also improve its profit estimates, though less than the higher-commission scenario.
These are brokerage estimates, not guaranteed outcomes or investment advice.
PB Fintech shares have fallen nearly 45% in recent weeks amid concern over proposed insurance commission limits.
Nomura cut its target price by 31% to Rs 1,100 and maintained a Neutral rating.
In its base case, Nomura cut its FY28 net profit estimate by 72% and its FY29 estimate by 51%.
Nomura’s alternative scenario with health insurance commission caps two percentage points higher lifts its FY28 net profit estimate 37% versus the base case.
A scenario including traditional savings products raises estimated net profit by 5–6% for FY28–FY29 and values the stock at Rs 1,366.
- Who
- PB Fintech and Japanese brokerage Nomura.
- What
- Nomura lowered its PB Fintech target price and revised its financial estimates in response to proposed insurance commission limits.
- When
- The share decline occurred in recent weeks; the article does not give a publication date.
- Where
- The report concerns PB Fintech and India’s insurance market.
- Why
- Nomura expects proposed commission caps and a possible exit from the POSP business to affect premiums, revenue and profits.
Potential pressures
Potential offsets
Proposed commission caps
Potential pressures
Nomura’s base case applies proposed commission caps and assumes PB Fintech exits the POSP business, contributing to lower premium and profit estimates.
Potential offsets
In an alternative scenario, Nomura assumes health insurance caps are two percentage points higher than proposed; it estimates FY28 net profit would be 37% above the base case.
New savings products
Potential pressures
The base case does not include the traditional savings-product scenario described by Nomura.
Potential offsets
Nomura assumes savings products reach 0.5–1.1% of premium mix in FY28–FY29 and estimates net profit 5–6% above the base case.
- Share price decline
- Nearly 45% in recent weeks.
- Nomura target price
- Reduced 31% to Rs 1,100 per share.
- Nomura rating
- Neutral.
- Current share price cited
- Rs 1,012 per share.
- Base-case FY28 net profit estimate
- Cut by 72%.
- Base-case FY29 net profit estimate
- Cut by 51%.
- Higher-cap scenario
- Assumes health insurance commission caps two percentage points above the proposal; FY28 net profit estimate is 37% above the base case.
- Savings-product scenario
- Assumes new savings products make up 0.5–1.1% of total premium mix in FY28–FY29; fair price estimated at Rs 1,366.